Design, Characterization, and In Vivo Pharmacokinetics of Tacrolimus Proliposomes

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery Systems
• Nanotechnology in Medicine

Background:

• Tacrolimus is an immunosuppressant drug with poor oral bioavailability.
• Developing effective drug delivery systems is crucial for improving tacrolimus efficacy.
• Proliposomes offer a promising approach to enhance the delivery of poorly soluble drugs.

Purpose of the Study:

• To develop and characterize proliposomal formulations of tacrolimus.
• To evaluate the in vitro and in vivo performance of tacrolimus proliposomes.
• To assess the potential of proliposomes to improve tacrolimus bioavailability.

Main Methods:

• Proliposomes were prepared using the thin film hydration method with various lipids (HEPC, SPC, DSPC, DMPC, DMPG) and cholesterol.
• Formulations were evaluated for particle size, zeta potential, in vitro drug release, and in vitro permeability (PAMPA, everted rat intestinal perfusion).
• In vivo pharmacokinetic studies were conducted in Sprague-Dawley rats to determine oral bioavailability.

Main Results:

• The optimal proliposome formulation (drug/DSPC/cholesterol 1:2:0.5) exhibited desirable particle size and zeta potential.
• Proliposomes demonstrated enhanced in vitro drug release and significantly improved tacrolimus permeability.
• In vivo studies showed a 193.33% relative bioavailability for the optimized proliposome formulation compared to tacrolimus suspension.

Conclusions:

• Proliposomal formulation significantly improves the absorption and bioavailability of tacrolimus.
• The developed proliposomes represent a viable strategy for enhancing tacrolimus oral delivery.
• This approach holds potential for improving therapeutic outcomes in patients requiring tacrolimus treatment.